hero bg

“It is in the Negev that Jewish scientific talent
and research ability shall be tested.”

David Ben-Gurion
Israel’s First Prime Minister

NIBN Management

Osnat Ohne, Ph.D.

Chief Executive Officer

Dr. Osnat Ohne joined the NIBN as CEO in December 2017, following years of experience in the innovative drug development industry where she held various managerial positions. Most recently, she served as COO at Tiltan Pharma Ltd., and prior to that, she was a Director Project Leader in Global Innovative R&D at Teva Pharmaceutical Industries for 10 years. During her years at Teva, Dr. Ohne led diverse innovative drug development projects, encompassing discovery, preclinical, and clinical development, for different types of drug product and disease indications, including experience in FDA regulations for the NCE and NTE route of developments. At Teva, she was also involved with due diligence and management of diverse academic projects, as well as bio startup companies, both in Israel and abroad, as part of Teva’s New Projects and Innovative Venture Unit. Over the years, Dr. Ohne served, in parallel, as an independent consultant to Israeli venture capitals, university technology transfer units, startup companies, and bio-accelerators, mainly for early stage innovative drug development projects. Dr. Ohne received her Ph.D. in immunology from Tel Aviv University's Sackler Faculty of Medicine’s Department of Microbiology in 2001.

Ron Lahav, Ph.D.

Executive Director - Research and Development

Dr. Ron Lahav became the NIBN’s Executive Director of R&D in September 2017. Dr. Lahav received his Ph.D. in biology from Ben-Gurion University of the Negev, and this was followed by a postdoctoral fellowship at Princeton University in the Department of Molecular Biology. He has been in the pharmaceutical industry for nearly 15 years, holding various leadership and executive management positions. After serving as a Senior Scientist at the Canadian company, AnorMed, until its acquisition by Genzyme, Dr. Lahav returned to Israel and joined Quark Pharmaceuticals as Project Director; he was quickly promoted to overseeing all projects in various fields such as CNS and oncology. Dr. Lahav was also the CEO of an incubator stage company called Quiet Therapeutics where he led the company from seed funding to a series C round. Following his position at Quiet, Ron held CEO positions at two early stage companies, SpliSense and ART Therapeutics.

Shlomit Kenigsberg, Ph.D. , MBA

Executive Director - Business Development

Dr. Shlomit Kenigsberg Joined NIBN’s Executive Director of Business Development in October 2021. Dr. Kenigsberg received her Ph.D. in Molecular Parasitology from Ben-Gurion University of the Negev, and an MBA with focus on marketing and leadership. After working as a field specialist at Qiagen- technologies for molecular diagnostics for 3 years, she returned for a postdoctoral fellowship at BGU focusing on infertility genetics. She moved to Canada in 2006, and served as a Senior Research Associate at Create Fertility Centre for nearly 10 years, where she established the clinics research institute, serving as the head of the Ovarian research group, forming collaborations, building research teams and applied science projects. Her expertise are liquid biopsies, exosomes (extracellular vesicles) and markers for infertility. Later on, Dr. Kenigsberg served as the COO/CTO of a Canadian Fertility clinics chain and recently returned to Israel after nearly 15 years. Dr. Kenigsberg is also a mental coach, personal development workshop facilitator and creative thinking workshops expert.

Keren Miller, Ph.D.

Executive Director - Intellectual Property

Dr. Keren Miller is a registered Patent Attorney with expertise in a variety of aspects related to Intellectual Property, including patentability evaluations, due diligence investigations, IP strategy, and portfolio management. Keren holds Ph.D. and M.Sc. degrees in Cancer Therapy from Tel-Aviv University, and a B.Sc. degree in Life Science from Ben-Gurion University. Keren has over 10 years of Intellectual Property experience in the Pharmaceutical and Biotechnology industry. She recently joined NIBN as the IP Executive Director.

Prof. Michael M. Meijler, Ph.D.

Scientific Executive Director

Prof. Michael Meijler obtained his M.Sc. degree in Chemistry from the University of Amsterdam and his Ph.D. degree from the Weizmann Institute of Science, under the supervision of Prof. Abraham Shanzer. He then performed postdoctoral research at Prof. Kim Janda lab at the Scripps Research Institute in La Jolla, California. After spending a year as an assistant professor at the Janda group in 2005, Prof. Meijler joined Ben-Gurion University of the Negev’s Department of Chemistry where he became a full professor in 2015. He has been a member of the NIBN since 2009, and he has served as the chair of the Department of Chemistry since August 2018. His research focuses on understanding chemical communication between bacteria themselves, and between bacteria and other species such as plants, fungi, and animals, in various settings. He is particularly interested in unraveling the role of chemical communication among human pathogens helps them in establishing persistent infections, and this knowledge may aid in the development of new therapeutic avenues to combat antibiotic resistance.

Maya Pitshadze, MBA

Executive Director - Finance

Maya Pitshadze holds an Executive MBA from Ben-Gurion University of the Negev and a BA in economics and computer science from Bar Ilan University. Ms. Pitshadze has over 18 years of experience in senior positions in the field of finance, including a position at an international pharmaceutical company. She has been at the NIBN since its founding and established the company’s financial and administrative systems.